![]() Consider the risks and benefits of each drug prior to transition. In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH WHO Group 1) to diminish symptoms associated with exercise. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |